News
High early recurrence rates with Merkel cell carcinoma
Approximately 95% of all recurrences happened within 3 years of the initial diagnosis in the prospective cohort study.
News
New hemophilia treatments: ‘Our cup runneth over’
A range of new options is emerging to treat hemophilia patients.
News
Handle with care: Managing IBD in older patients
Patients 60 and older with chronic or newly diagnosed IBD may have comorbidities or use medications that can interfere with IBD therapies.
News
Malnutrition common in patients with IBD
As many as 85% of patients hospitalized with IBD may be malnourished, dietary experts cautioned.
News
Breakthrough COVID-19 milder in vaccinated patients with IBD
Patients with inflammatory bowel disease who are vaccinated but still develop COVID experience milder disease than those who are unvaccinated.
News
ARFID or reasonable food restriction? The jury is out
Don’t jump to conclusions about avoidant restrictive food intake disorder in patients with gastrointestinal diseases, psychologists advise.
News
Monotherapy or one-two punch against EGFR-mutant NSCLC?
Clinicians debate whether combining other drugs with osimertinib adds anything but toxicity to the care of patients with EGFR-mutated NSCLC.
News
DKMS: Small nonprofit to world’s largest stem cell donor registry
A German family’s tragedy launched DKMS, a multinational organization whose goal is to “delete blood cancer.”
News
TKI/BiTE combo extends survival of older patients with Ph+ALL
In these elderly patients who are not candidates for chemo, the issue is whether we can prolong remission by the addition of other treatments,...
News
Adaptive therapy borrows from nature to keep rhabdomyosarcoma in check
Researchers are applying evolutionary principles to the treatment of childhood, fusion-positive rhabdomyosarcoma.
News
AGILE: ‘Exciting’ survival results for IDH1-mutated AML
Results show survival that is three times longer for a combination of ivosidenib plus azacitidine versus azacitidine alone in a distinct...
News
Isatuximab added to RVd boosts response in new myeloma
A drug approved in 2020 for treatment of advanced multiple myeloma has been shown to benefit patients newly diagnosed with the disease.
News
‘Outstanding data’: Mosunetuzumab in r/r follicular lymphoma
If approved by the FDA, mosunetuzumab has the potential to be a first-in-class CD20xCD3 T-cell engaging bispecific antibody in non-Hodgkin...